1. Use of a composition for the manufacture of a product for improving or maintaining the functional connection of the brain, and / or functional synaptic activity and / or the network organization of the brain in a subject in need thereof, and / or delay in onset, or prevent recovery of impaired cerebral functional relationship and / or impaired functional synaptic activity and / or impaired brain network organization in a subject in need thereof, wherein said composition comprises: i) one or more of the following substances: uridine and cytidine or their salts, phosphates, acyl derivatives or esters and ii) a lipid fraction comprising at least one of docosahexaenoic acid (22: 6 DHA), eicosapentaenoic acid (20: 5, EPA) and docosapentaenoic acid (22: 5 KDP), or their complex efiry.2. Use of a composition for the manufacture of a product for the treatment of subject in need thereof, wherein said composition comprises: i) one or more of the following substances: uridine and cytidine or their salts, phosphates, acyl derivatives or esters and ii) a lipid fraction comprising at least one of docosahexaenoic acid (22: 6 DHA), eicosapentaenoic acid (20: 5, EPA) and docosapentaenoic acid (22: 5 WPC) or ihslozhnye ethers, and wherein said subject exposed imaging procedure in order to assess or monitor brain functional link and / or network organization mozga.3 head. A method of improving or maintaining the functional link and / or network organization of the brain in a subject in need thereof, said method comprising administering to said subject a composition comprising: i) one and1. Применение композиции для производства продукта для улучшения или сохранения функциональной связи головного мозга, и/или функциональной синаптической активности, и/или сетевой организации головного мозга у нуждающегося в этом субъекта, и/или замедления возникновения, предотвращения или восстановления нарушенной функциональной связи головного мозга, и/или нарушенной функциональной синаптической ак
